ABSTRACT
In 1853, the perception of prostate cancer (PCa) as a rare ailment prevailed, was described by the eminent Londoner surgeon John Adams. Rapidly forward to 2018, the landscape dramatically altered. Currently, men face a one-in-nine lifetime risk of PCa, accentuated by improved diagnostic methods and an ageing population. With more than three million men in the United States alone grappling with this disease, the overall risk of succumbing to stands at one in 39. The intricate clinical and biological diversity of PCa poses serious challenges in terms of imaging, ongoing monitoring, and disease management. In the field of theranostics, diagnostic and therapeutic approaches that harmoniously merge targeted imaging with treatments are integrated. A pivotal player in this arena is radiotheranostics, employing radionuclides for both imaging and therapy, with prostate-specific membrane antigen (PSMA) at the forefront. Clinical milestones have been reached, including FDA- and/or EMA-approved PSMA-targeted radiodiagnostic agents, such as [18F]DCFPyL (PYLARIFY®, Lantheus Holdings), [18F]rhPSMA-7.3 (POSLUMA®, Blue Earth Diagnostics) and [68Ga]Ga-PSMA-11 (Locametz®, Novartis/ ILLUCCIX®, Telix Pharmaceuticals), as well as PSMA-targeted radiotherapeutic agents, such as [177Lu]Lu-PSMA-617 (Pluvicto®, Novartis). Concurrently, ligand-drug and immune therapies designed to target PSMA are being advanced through rigorous preclinical research and clinical trials. This review delves into the annals of PSMA-targeted radiotheranostics, exploring its historical evolution as a signature molecule in PCa management. We scrutinise its clinical ramifications, acknowledge its limitations, and peer into the avenues that need further exploration. In the crucible of scientific inquiry, we aim to illuminate the path toward a future where the enigma of PCa is deciphered and where its menace is met with precise and effective countermeasures. In the following sections, we discuss the intriguing terrain of PCa radiotheranostics through the lens of PSMA, with the fervent hope of advancing our understanding and enhancing clinical practice.
Subject(s)
Antigens, Surface , Glutamate Carboxypeptidase II , Prostatic Neoplasms , Radiopharmaceuticals , Humans , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/therapy , Glutamate Carboxypeptidase II/metabolism , Male , Antigens, Surface/metabolism , Radiopharmaceuticals/therapeutic use , Nuclear Medicine/methods , Nuclear Medicine/history , Theranostic Nanomedicine/methods , Radioisotopes/therapeutic use , History, 21st Century , History, 20th CenturySubject(s)
Nuclear Medicine , History, 20th Century , History, 21st Century , Nuclear Medicine/history , HumansSubject(s)
Cardiology , Humans , Cardiology/history , Cardiology/trends , Nuclear Medicine/history , Nuclear Medicine/trends , History, 21st Century , Forecasting , History, 20th Century , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/therapy , Predictive Value of Tests , Myocardial Perfusion Imaging/methodsABSTRACT
Gated radionuclide angiography and myocardial perfusion imaging were developed in the United States and Europe in the 1970's and soon adopted in Canadian centers. Much of the early development of nuclear cardiology in Canada was in Toronto, Ontario and was quickly followed by new programs across the country. Clinical research in Canada contributed to the further development of nuclear cardiology and cardiac PET. The Canadian Nuclear Cardiology Society (CNCS) was formed in 1995 and became the Canadian Society of Cardiovascular Nuclear and CT Imaging (CNCT) in 2014. The CNCS had a major role in education and advocacy for cardiovascular nuclear medicine testing. The CNCS established the Dr Robert Burns Lecture and CNCT named the Canadian Society of Cardiovascular Nuclear and CT Imaging Annual Achievement Award for Dr Michael Freeman in memoriam of these two outstanding Canadian leaders in nuclear cardiology. The future of nuclear cardiology in Canada is exciting with the expanding use of SPECT imaging to include Tc-99m-pyrophosphate for diagnosis of transthyretin cardiac amyloidosis and the ongoing introduction of cardiac PET imaging.
Subject(s)
Cardiology , Nuclear Medicine , Positron-Emission Tomography , Humans , Canada , Nuclear Medicine/history , History, 20th Century , Cardiology/history , History, 21st Century , Societies, Medical , Myocardial Perfusion ImagingSubject(s)
Nuclear Medicine , History, 20th Century , History, 21st Century , Nuclear Medicine/history , HumansSubject(s)
Neoplasms , Nuclear Medicine , Humans , Quality of Life , Nuclear Medicine/history , Neoplasms/therapyABSTRACT
During the last 100 years, musculoskeletal radiology has developed from bone-only radiography performed by everyone to a dedicated subspecialty, still secure in its origins in radiography but having expanded into all modalities of imaging. Like other subspecialties in radiology, it has become heavily dependent on cross-sectional and functional imaging, and musculoskeletal interventions play an important role in tumor diagnosis and treatment and in joint diseases. All these developments are reflected in the pages in Acta Radiologica, as shown in this review.
Subject(s)
Musculoskeletal System/diagnostic imaging , Periodicals as Topic/history , Radiology/history , Angiography/history , Arthrography/history , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/history , Fractures, Bone/diagnostic imaging , Fractures, Bone/history , History, 20th Century , History, 21st Century , Magnetic Resonance Imaging/history , Muscle Neoplasms/diagnostic imaging , Muscle Neoplasms/history , Nuclear Medicine/history , Radiology, Interventional/history , Tomography, X-Ray Computed/history , Tuberculosis, Osteoarticular/diagnostic imaging , Tuberculosis, Osteoarticular/history , Ultrasonography/historySubject(s)
Cardiology/history , Nuclear Medicine/history , Career Choice , History, 20th Century , History, 21st Century , Humans , Leadership , United StatesABSTRACT
Nuclear medicine (NM) is a medical specialty that uses radionuclides (radioactive tracers) and ionising radiation for diagnostic and therapeutic (theranostic) purposes. Nuclear medicine arose and developed at the intersection of physics, chemistry and clinical medicine. The radiation emitted by radioisotopes can consist of gamma-, beta- and alpha emission, or it's combination. Radioisotope of choice for medical purposes should have futher requirements: low radiotoxicity, suitable type of radiation, energy and half-life (several minutes to several hours and days), and also convenient detection of gamma ray radiation. The radionuclide is part of radiopharmaceutical (RP) and acts as its indicator. RP accumulates in morphological structures, becomes a carrier of coordinated information from patient to gamma camera or other equipment and reflects the dynamics of processes occurring in the examined organ. In 2021 NM celebrates its 80th anniversary. The trajectory of NM combines modern methods of radiotheranostics and applied genomic and post-genomic technologies.
Subject(s)
Nuclear Medicine , Radioisotopes , Half-Life , Humans , Nuclear Medicine/history , Radioisotopes/therapeutic use , Radionuclide Imaging , Radiopharmaceuticals/therapeutic useABSTRACT
No disponible